Abstract
Thirty-one patients were entered into a pilot study combining oral quinidine with epirubicin 100 mg m-2 as first line chemotherapy in advanced breast cancer. Three patients were treated with quinidine 1 g b.d., and developed symptoms of toxicity. Of eight subsequent patients treated with quinidine 500 mg b.d., two experienced tiredness and nausea and one severe oral toxicity with epirubicin. The remaining 20 patients received quinidine 250 mg b.d.; one developed cinchonism and one malaise, the remainder showing no excess toxicity compared with epirubicin alone. The median nadir WBC was similar with or without quinidine (2.3 vs 1.6 x 10(9) l-1) as was median nadir platelet count (175 vs 157 x 10(9) l-1). There was no evidence of significant cardiac toxicity. The median plasma quinidine level achieved was 5.6 mumol l-1 (range 2.1-22.1), which is within the range of concentrations which is effective in vitro at reversing experimental anthracycline resistance. A randomised controlled study is proposed to assess the impact of this potential modulation on the efficacy of epirubicin in advanced breast cancer.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Jones, R., Kerr, D., Harnett, A. et al. A pilot study of quinidine and epirubicin in the treatment of advanced breast cancer. Br J Cancer 62, 133–135 (1990). https://doi.org/10.1038/bjc.1990.244
Issue Date:
DOI: https://doi.org/10.1038/bjc.1990.244
This article is cited by
-
Prochlorperazine as a doxorubicin-efflux blocker: phase I clinical and pharmacokinetics studies
Cancer Chemotherapy and Pharmacology (1993)
-
Chemosensitisation of a drug-sensitive parental cell line by low-dose cyclosporin A
Cancer Chemotherapy and Pharmacology (1991)